Enbrel, Prolia Suffer FDA’s Combination Punch On Device Components
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen did not follow proper procedures when it switched from one Enbrel vial adapter to another, FDA says, a change that led to an uptick in product complaints.
You may also be interested in...
Kineret GMP Warning Letter Prompts Changes To Internal Amgen Inspections
Amgen is making global changes to its internal inspection procedures in response to a warning letter from FDA
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.